Including the identified MET amplification, 34.3% of CCA patients harbored mutations and CNAs in oncogenes from the RTK-RAS pathway, and these alterations occurred in a mutually exclusive manner, as reported in other cancers (Supplementary Fig. 2A). The gene discussed is MET; the disease is cholangiocarcinoma.